Each filovirus virion has one single-stranded molecule of negative-sense RNA. Transcriptional start and termination signals define and conserve genes within the virus, which are linearly arranged.

LONDON--(BUSINESS WIRE)--Virion Biotherapeutics announced today the appointments of Vanessa King, PhD, as President & Chief Executive Officer and Isabel Najera, PhD, as Chief Scientific Officer.

PHILADELPHIA, Sept. 26, 2018 /PRNewswire/ -- A new Philadelphia-based start-up, Virion Therapeutics, LLC spun out of The Wistar Institute, will work to advance innovative, immune-based therapies ...

Ocean Biomedical, Inc. (NASDAQ: OCEA) announces that its joint venture partner, Virion Therapeutics, has dosed its first patient in the Phase 1b clinical trial of its investigational VRON-0200 ...

Philadelphia PA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Virion Therapeutics, LLC, developer of immunotherapies for cancer and chronic infectious diseases that utilize genetically encoded checkpoint ...

Wistar Institute spinout company Virion Therapeutics raised a $4 million angel round, according to an SEC filing. The immunotherapy company is working on a path to commercialization for a set of ...

Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a ...